This is a specific type of cancer that starts in the nervous system, usually in children. It grows outside the brain and spinal cord, often in soft tissues or bones. It's called 'peripheral' because it's not in the central nervous system. These tumors are often aggressive and require treatment.
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for Peripheral Primitive Neuroectodermal Tumors?
Peripheral primitive neuroectodermal tumor (pPNET) is an older name for Ewing sarcoma, a cancer that forms in bone or in the soft tissues that connect and support the body, such as muscle. Doctors once treated pPNET, Ewing sarcoma of bone, Askin tumor (Ewing sarcoma of the chest wall) and extraosseous Ewing sarcoma (Ewing sarcoma outside bone) as related but separate tumors. Gene and tissue studies showed they are the same cancer, so today most specialists and treatment guidelines use the single name Ewing sarcoma. It is different from brain tumors that were once also called primitive neuroectodermal tumors, which are a separate disease with different treatment. It is rare and most common in teenagers and young adults, though it can occur in younger children and older adults. It often starts in the legs, arms, pelvis, ribs or spine. The usual first sign is pain, swelling or a lump near the tumor, which can be mistaken for an injury. Some people also have fever without an obvious cause, tiredness, weight loss or a bone that breaks with little or no injury. Because it grows quickly and can spread, it needs prompt diagnosis and treatment at a specialist center.
Ewing sarcoma is driven by a change inside the tumor cells in which two genes become joined. The resulting fusion gene switches on growth signals the cell should not have. This change happens in the tumor itself. It is not something a person inherits or passes to their children, and it is not caused by anything the person or their parents did. Very few risk factors are known. The cancer is about nine times more common in White people than in Black people in the United States, with Asian people in between, partly because of common inherited gene variations that are more frequent in White people. It is slightly more common in males. Children with Fanconi anemia, an inherited condition affecting the bone marrow, may have a higher risk. Most people who develop Ewing sarcoma have no known risk factor.
Diagnosis starts with an X-ray and an MRI (magnetic resonance imaging) of the painful or swollen area, which show the tumor's size and how far it extends into nearby tissue. The diagnosis is confirmed with a biopsy, in which a needle or small incision removes a piece of the tumor. Where the biopsy is taken matters: a poorly placed biopsy can lead to wider surgery or a larger radiation field later, so it is best done by, or planned with, the team that will treat the cancer. Under the microscope Ewing sarcoma looks like many other "small round cell" tumors, so the sample is tested for the characteristic gene fusion. These gene tests also separate Ewing sarcoma from look-alike sarcomas, grouped as undifferentiated small round cell sarcomas, which are distinct diseases even though they are often treated in a similar way. Staging tests then check whether the cancer has spread. These usually include a CT (computed tomography) scan of the chest, a PET (positron emission tomography) scan or a bone scan, and blood tests including LDH (lactate dehydrogenase, an enzyme that tends to be higher with larger or more widespread tumors). A bone marrow biopsy may be added if other tests suggest spread. About one in four people already has detectable spread at diagnosis, most often to the lungs, other bones or bone marrow.
Treatment combines chemotherapy for the whole body with treatment aimed at the original tumor. Even when scans show the cancer only in one place, small amounts have usually spread unseen, so everyone receives chemotherapy. It usually comes first, to shrink the tumor and attack hidden cancer cells, and the full course lasts roughly 6 to 12 months. In the United States the standard combination alternates two sets of drugs: vincristine, doxorubicin and cyclophosphamide, then ifosfamide and etoposide. Side effects are significant. These chemotherapy drugs lower blood counts, which makes infections more likely, so the team checks blood counts and other effects throughout each cycle. The original tumor is treated with surgery, radiation or both, a step called local control. Surgery is generally preferred when the tumor can be removed without losing important function. Radiation is used when the tumor cannot be removed, when surgery would cost too much function or change appearance significantly, or when cancer cells remain at the edges after surgery. For a tumor in a leg or arm, surgeons can often save the limb and rebuild the bone, though amputation is sometimes the better choice. When the cancer has spread, the same treatments are used on both the main tumor and the areas of spread, sometimes including radiation to both lungs when the cancer has spread there. Cancer that returns after treatment is treated with different chemotherapy combinations, radiation or surgery, and clinical trials are an important option at that stage. Care is best planned by a team experienced in Ewing sarcoma, which can include oncologists, orthopedic surgeons, radiation oncologists, rehabilitation specialists, psychologists, social workers and fertility specialists.
Treatment is long and demanding. Most of a year is usually spent in chemotherapy cycles, with surgery or radiation partway through, and school, work and family routines are disrupted. Rehabilitation after limb surgery can take months, and physical therapy helps people regain strength and mobility. Because chemotherapy and radiation can affect future fertility, options for preserving it are best discussed before treatment starts. Outlook depends most on whether the cancer has spread at diagnosis. With current treatment, about 70% of people whose cancer is localized are alive and free of disease five years later. When it has spread, the cure rate is much lower, around 20% overall, though people whose spread is limited to the lungs do better than those with spread to bones or bone marrow. Age, tumor size and location, and how much of the tumor is destroyed by the first chemotherapy also affect outlook. After treatment ends, regular check-ups with scans continue for years, because the cancer can come back and because problems from treatment can appear months or years later. These late effects can include heart and lung damage, effects on growth and development, infertility, changes in thinking, learning or memory, and second cancers such as leukemia or a new sarcoma in an area treated with radiation. Follow-up with clinicians trained in late effects helps find and manage these problems early.
See a doctor about bone or joint pain, swelling or a lump that persists, keeps getting worse, or comes with unexplained fever, tiredness or weight loss. These symptoms usually have another cause, but pain that does not follow the pattern of an injury deserves an X-ray. A bone that breaks after little or no injury also needs evaluation. For someone with a known or suspected tumor, new back pain with weakness, numbness or trouble walking can mean the tumor is pressing on the spinal cord. Contact the care team right away, because this needs to be seen the same day. New shortness of breath, which can signal cancer in the lungs, also needs a prompt call. During chemotherapy, a fever of 100.4°F (38°C) or higher, or chills, needs a call to the care team right away, day or night, because infection can become serious quickly when blood counts are low. Follow the team's instructions about other symptoms that need an urgent call. After treatment, report new pain, swelling or other changes promptly rather than waiting for the next scheduled visit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Peripheral Primitive Neuroectodermal Tumors is like, what's helped you, or ask the community a question.